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Beyond public health genomics: proposals from an international working
group
Advances in genomics have crucial implications for public health,
offering new ways of differentiating individuals and groups within
populations that go beyond the measures normally used by public
health professionals, such as gender, age, socio-economic status,
physiological measurements or clinical biomarkers.1 While public
health has traditionally been concerned with interventions at a
population level, genomic medicine seems to promote a vision for
health care that encourages individualism rather than collectivism.2
This tension is apparent in weighing up its consequences. Thus, it
may bring benefits in stratifying individuals according to genetic
risk, enabling better targeting of preventive and therapeutic inter-
ventions. But it may also have harmful consequences undermining
the imperative to tackle social and environmental determinants of
disease and the collective provision of health care potentially leading
to overdiagnosis/overtreatment; it may fragment the risk pooling
that underpins social solidarity; and it may increase the probability
of stigmatization and discrimination.
Consequently, the public health community, with its commitment
to equity, must take the opportunity to engage with genomic
knowledge, ensuring that it advances the population’s health.
These issues were explored in January 2014 at the inaugural
meeting of an international working group on ‘Beyond Public
Health Genomics’, convening leading experts in genomics, public
health, clinical sciences, systems medicine, law and bioethics, from
many disciplines and countries, at the Universita` Cattolica del Sacro
Cuore in Rome. Its goal, inspired by the 2005 Bellagio statement on
public health genomics, defined as the ‘responsible and effective
translation of genome-based discovery into population health,3
was to generate high value-based proposals to foster the evidence
base for implementing genomic discoveries in public health policy
and practice, and to ensure necessary action while accounting for the
challenge of needing to fund these workstreams in the current
environment of diminishing resources.
The contribution of genomics to health is in three main areas. The
first is the ability to go beyond traditional phenotypes using genetic
and molecular characteristics as a basis for diagnosis and disease
classification. Sequencing and other molecular technologies may
facilitate the diagnosis in difficult cases, such as children born
with learning disability or developmental delay. Newborn
screening programmes enable early diagnosis and treatment for a
range of rare inherited metabolic conditions before clinical presen-
tation, thereby improving length and quality of life for affected
children. Cancers may now be subdivided into different types
according to their genetic or molecular signature, as can diabetes,
sudden cardiac death and a range of other conditions. For example,
women with BRCA1 mutations may be identified through genetic
testing with a view to offer more intensive preventive options,
including mammographic screening, chemotherapy or prophylactic
surgery.
The second is to guide treatment, the first emerging area being
that of pharmacogenomics. The ability to refine diagnostic
categories will allow specific treatments, whether in oncology,
cardiology or diabetes care. It may also be possible to differentiate
patients according to how they metabolize drugs more accurately
tailoring the dosages, or to ascertain those at greatest risk of adverse
drug reactions. This has obvious benefits not only for the patient but
also the health-care system as a whole because resources will provide
only the most effective treatments, thus improving outcomes and
reducing waste.
The third is to stratify populations according to disease risk or
resistance so as to maximize benefits of prevention programmes,
using algorithms computed from both genetic and non-genetic
parameters. This approach, sometimes termed genetic profiling, is
in its infancy and its utility has yet to be shown, as individuals who
carry multiple risk alleles and a high risk of disease will likely
constitute only a small percentage of the population.
The participants noted a fourth contribution resulting from the
appropriate use of pathogen genomics in infectious disease control,
but with the meeting’s focus on human genomics, its contribution
was not further discussed.
To date, genomics has had only limited impact on health policy
and practice. Khoury et al.4 have described genomic research as
falling on a continuum from the initial discovery (T0) to T1,
developing candidate health applications; T2, evaluating its applica-
tions and developing evidence-based recommendations; T3,
integrating evidence-based recommendations into health care and
prevention; and finally T4, assessing health outcomes and
population impact. They noted that the vast majority of published
research remains in the discovery phase, with a few making it to the
early stages of translation. But since that paper was written and
published, science and technology have advanced rapidly.
Notwithstanding frequent calls to support more translational
research and actual implementation of proven genomic interven-
tions, in reality, there have been few efforts to evaluate recent
discoveries to see whether they are effective in the real world and,
if so, for whom and in which circumstances.5
Evans and colleagues have proposed some ways in which the
potential of public health genomics might be realized.6 Rapid and
inexpensive sequencing of genes can identify individuals carrying
individually rare mutations that confer substantial predisposition
to preventable diseases. Examples include use of BRCA1 and
BRCA2 gene testing for hereditary breast cancer: their combined
prevalence is around 0.2–0.3% of the general population, but they
confer a >70% lifetime risk for breast and ovarian cancer. Also, the
four Lynch-associated genes are present in 0.2% of subjects and
confer >80% lifetime risk for colon cancer, with potential risk
reduction by colonoscopy and prophylactic aspirin treatment.
These are obvious candidates for further evaluation to assess
whether there is a case for their wider use, drawing on the
experience with some existing neonatal screening programmes,
such as that for phenylketonuria, where the prevalence of the
genetic disorder is much rarer.7 Nevertheless, it is clear that such
proposals should be subjected to rigorous evaluation using the
screening criteria frameworks usually used for screening
programme decisions.
We have already noted that the use of genetic profiling for
prevention of common disorders presents major challenges, not
least because at present there is little evidence that better
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knowledge of one’s genetic makeup will lead to behaviour change
enhancing health if the underlying risk is not very high.8 Worse, it
may engender fatalism and anxiety. Other key issues to be addressed
include judgements about equity, service effectiveness and
prioritization. But, the lack of evidence of utility is not the same
as evidence of disutility, and there may in the future be room to
refine and integrate genomic information for the prevention of
common complex disorders.
So is the incorporation of genomics for prevention and public
health use a paradigm shift in public health or a marginal
increment? The international working group recognizes that the
genetic characteristics of an individual or a population are only
one set of factors that will determine the pattern and distribution
of health and disease. Most obviously, there is a need to understand
gene–environment interactions, exemplified by a recent paper that
demonstrated the interaction between a genome-derived risk score
and consumption of fried foods in increasing the probability of
becoming obese.9 However, this is still based on single genes,
whereas the obvious next step to tackle complex forms of disease
will be to involve multiple genes and environmental factors.
Further, the public health community can integrate this work with
contributions from other ‘omics’, including the related fields of
epigenomics, proteomics and metabolomics, noting, of course,
that all of these factors are embedded within the broader social
and economic determinants of health. There is a corresponding
need for those working at the molecular level to address the social
and economic determinants of public health, and to acknowledge
the contribution of existing clinical interventions, the combined
effects of which have achieved a decline of up to 50% in cardiovas-
cular deaths in the past three decades in many industrialized
countries.
Our proposal is therefore a call for greater engagement by those
from public health, with geneticists and scientists to engage with
modern genomic and molecular science to develop evidence-based
approaches for addressing translational barriers of the kind
identified above. Two areas of research were identified as low-
hanging fruit:
 Effectiveness and cost-effectiveness research of new genomics-
based approaches
 Implementation research that aims to assist the decision-making
processes in genomic medicine and its use in disease prevention
Outwith the research agenda, practical solutions to effectively
translate research findings within health systems will also be
needed. This will mean investment through a separate funding
stream to ensure that the fruits of such research are actually acted
upon and implemented in the real world of policy makers, clinical
practitioners and health service managers, a community with
different objectives, reward strategies and culture. Additionally,
changes will be needed in the practice of public health that aim to
integrate advances in genomics into public health competencies and
training, and to establish appropriate policy and ethical frameworks
to ensure that genomic technologies and information improve
health across all segments of the population.
In conclusion, there may be potential to reduce the burden of
disease and improve population health through genomics, but we
believe that it will be most successful if it is developed as a natural
extension of traditional public health approaches. Achieving total
integration of the two will require that practitioners work
together. Decision-makers in health and science policy may be
reluctant to engage not least because of fear of the financial and
organizational implications of innovation. Academics may also
have a similar reluctance because of their focus on research and
lack of attention to the implications of findings for public policy.
Public health professionals have a duty to engage in this agenda.
Otherwise, there is a danger that the field will be open for those
whose motivations are primarily commercial and incompatible with
notions of equity and the promotion of health for all. Horizon 2020
challenges researchers in the field of public health to take public
health into the genomics era, in particular through its theme of
‘Piloting personalized medicine into health and care systems’.10
The public health and policy communities have no real alternative
but to engage; the failure to do so can have only adverse conse-
quences for population health.
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